Patent 11299465 was granted and assigned to Sumitomo Dainippon Pharma Co., Ltd. on April, 2022 by the United States Patent and Trademark Office.
The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: